Epstein-Barr Virus- (EBV-) Immortalized Lymphoblastoid Cell Lines (LCLs) Express High Level of CD23 but Low CD27 to Support Their Growth
Table 3
Surface marker expression of PBMCs and LCLs derived from participated subjects.
Sample type and annotation
Surface marker expression (%) standard deviation
CD3+
CD19+
CD19+CD23+
CD19+CD27+
CD19+CD23+CD27+
1B
PBMC-1B
66.58
5.62
3.92
0.36
0.01
LCL-1B
0.02
81.19 0.77
49.26 1.26
17.75 1.51
6.63 0.93
2C
PBMC-2C
78.72
6.07
5.57
1.56
0.41
LCL-2C
0.06 0.03
86.61 0.38
39.57 0.25
53.66 0.56
20.59 0.31
5B
PBMC-5B
44.10
14.02
7.97
3.73
0.25
LCL-5B
0.09 0.05
79.47 0.31
38.52 0.16
51.5 1.03
19.09 0.68
6A#
PBMC-6A
-
19.4
19.5
3.7
1.0
LCL-6A#
-
77.4
27.4
39.7
11.06
7B
PBMC-7B
72.27
10.95
8.70
1.49
0.22
LCL-7B
0.01 0.02
80.58 1.28
48.06 1.29
23.34 5.76
8.79 3.13
8A
PBMC-8A
66.6
16.2
17.9
2.34
1.24
LCL-8A
0.14 0.21
86.0 0.83
58.9 2.58
34.4 4.90
17.6 1.37
9D
PBMC-9D
49.57
2.56
2.06
0.18
0.03
LCL-9D
0.02 0.01
71.32 0.87
43.17 0.70
15.74 0.28
5.72 0.22
10E
PBMC-10E
34.15
23.58
22.57
3.89
0.64
LCL-10E
0
76.59 0.51
44.72 0.24
43.94 0.03
19.54 0.18
11A
PBMC-11A
59.45
13.02
8.75
3.74
0.57
LCL-11A
0.05 0.01
68.59 0.73
16.94 0.37
48.83 1.10
8.89 0.30
12A
PBMC-12A
48.27
9.10
7.58
5.42
0.53
LCL-12A
0.05 0.01
72.70 1.20
18.29 0.40
51.64 1.11
9.73 0.21
13B
PBMC-13B
29.78
45.95
13.61
1.65
0.10
LCL-13B
0.01 + 0.01
74.95 + 1.42
52.87 + 1.54
20.18 + 1.51
12.74 + 1.2
15A
PBMC-15A
10.46
2.35
1.93
1.12
0.11
LCL-15A
0
88.84 + 1.72
19.47 + 0.46
80.89 + 0.82
17.78 + 0.49
16A
PBMC-16A
81.8
9.66
9.74
2.66
0.82
LCL-16A
0.27 0.41
72.8 0.64
43.7 1.81
50.6 8.63
26.0 3.05
17A
PBMC-17A
69.28
11.64
10.66
3.39
0.61
LCL-17A
0
89.35 + 1.03
41.15 + 2.07
80.06 + 1.59
41.53 + 0.65
C
PBMC-C
75.5
16.3
15.4
1.85
0.59
LCL-C
0.10 0.14
70.6 1.73
44.1 4.04
37.9 0.24
17.6 1.80
LCL: lymphoblastoid cell line; PBMC: peripheral blood mononuclear cell. #Flow cytometric analysis for all surface markers was only performed once and CD3 levels were not determined due to the limitation of cell number.
